Median overall survival was 15.6 vs. 8.4 months and median progression-free survival was 2.9 vs. 1.7 months in patients with liposarcoma treated with ...
Approval was based on improvement in overall survival in CheckMate 025, an open-label, randomized study of 821 patients with advanced renal cell carci...
Approval was based on an objective response rate of 29% with a median response duration of 7.4 months in 106 patients with relapsed or refractory mult...
